Poor
Mostly Aligned
Patient Risk:
Low
Summary
Most claims are not supported by the supplied FDA label text (approval/market-history and duration-of-use statements). Only indication-related claims for MI/stroke/PAD and ACS align with the provided sections.
Category Scores
Accurate Statements
Plavix is used in people with a history of heart attack.
Section 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease
Plavix is used in people with a history of stroke.
Section 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease
Plavix is used in people with peripheral artery disease.
Section 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease
Plavix is used for certain patients after acute coronary syndromes.
Section 1.1 Acute Coronary Syndrome (ACS)
Unsupported Statements
Plavix (clopidogrel) has been around since the late 1990s.
Not supported by the supplied FDA label sections (approval/market-history statements absent).
Plavix was first approved by regulators in Europe in 1998.
European approval date absent from the supplied FDA label sections.
Plavix reached the U.S. market in 1997.
U.S. market timeline absent from the supplied FDA label sections.
If counted from the first U.S. approval (1997), Plavix has been in use for about 28–29 years as of 2026.
Label does not provide duration-of-use calculations or historical timelines.
If counted from the first European approval (1998), Plavix has been in use for about 27–28 years as of 2026.
Label does not provide European approval timelines or duration-of-use calculations.
Plavix has remained a widely used antiplatelet medication for decades.
General utilization/market prevalence statements are absent from the supplied FDA label sections.
Contradictions
Low
AI Statement
Plavix is used for certain patients after stents.
Label Reference
Section 1.1 Acute Coronary Syndrome (ACS) (includes patients managed with coronary revascularization); supplied label text does not explicitly mention 'stents.'
Important Omissions
No dosage and administration details were provided in the evaluated response, despite availability of label sections on indications only; therefore label-adherence for dosing could not be assessed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The non-supported claims are primarily historical/market-history assertions rather than dosing, safety, or contraindication statements. Indication statements that are supported do not, by themselves, create dosing/safety errors. A minor specificity issue exists regarding 'stents' vs 'coronary revascularization' wording.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple claims about approval dates, market entry, and duration of use are not supported by the supplied FDA label text.
Suggested Improvement
Remove or reframe approval/market-history and duration-of-use statements; restrict claims to the label-supported indications in Sections 1.1 and 1.2, and avoid 'stents' unless explicitly supported by the provided label text.